Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IBRX)

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

PR Newswire 2 days ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

PR Newswire 5 days ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Business Wire 5 days ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

Business Wire 12 days ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Business Wire October 24, 2024

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Business Wire October 21, 2024

IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

PR Newswire October 11, 2024

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer 

Business Wire September 9, 2024

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Business Wire August 12, 2024
View More News ››

Opinion & Analysis (NDAQ:IBRX)

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Streetwise Reports January 17, 2020

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015
View More Opinion ››

Bullboard Posts (NDAQ:IBRX)

Objective long/short (IBRX) Report

BREAKING NEWS: $IBRX Objective long/short (IBRX) Report2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using...
whytestocks - July 7, 2024

Why ImmunityBio Stock Is Trading Higher Thursday | Benzinga

NEWS: $IBRX Why ImmunityBio Stock Is Trading Higher Thursday | BenzingaImmunityBio, Inc. (NASDAQ:IBRX) shares are moving higher Thursday...
whytestocks - June 20, 2024

ImmunityBio Announces Positive Overall Survival Results of A

News; $IBRX ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell...
whytestocks - April 25, 2024

South Africa to make Immunities Vac.

ImmunityBio's COVID-19 Vaccine Will Be Manufactured In South Africa: Bloomberg (yahoo.com)
tturner617 - March 19, 2021

Feb 5 21.. Pill Now being tested

In S. Africa....  Covid vaccine pill enters clinical trials - Research Professional News
tturner617 - February 7, 2021

doubled investment in 3 weeks

Id say NK has considerable upside yet. They are on the warp 14 list for covid 19 vaccine development, their serum base has already been...
Covey1000 - June 3, 2020
View more Bullboard ››

Mirasol Resources Ltd.

Mirasol Resources Ltd.

Mirasol Resources Ltd. is a Canada-based mineral exploration company focused on quality copper, gold and silver discoveries ...
View More »